Amplified Sciences, Inc. Competitors

Founded in 1990 and headquartered in San Diego, California, ChemDiv is a contract research organization providing development solutions to pharmaceutical and biotech companies.

Eutropics Pharmaceuticals, Inc. is developing PRIMAB-Dx, a clinically deployable functional biomarker platform that directly measures cancer cell survival dependencies on BCL-2 family proteins to guide apoptosis-targeted therapies in AML and other hematologic malignancies. Unlike research-grade functional assays, PRIMAB-Dx is being validated within a CLIA framework with a clear RUO-to-CLIA revenue model, making it immediately deployable for pharma partners running BH3 mimetic and apoptosis-targeted clinical trials. The platform addresses the critical unmet need of matching therapy to a patient's actual tumor physiology — not simply their disease classification. The company was founded by Michael Cardone, Ph.D. and a team of scientific founders and advisors with deep expertise in oncology drug and biomarker development, including Michael Andreeff, M.D., Ph.D. (MD Anderson), Alan D'Andrea, M.D. (Dana-Farber/Harvard), and Kevin Kelly, M.D. (USC Keck School of Medicine). Eutropics has raised over $21 million in non-dilutive grants, angel investment, and revenues, and maintains active research collaborations with MD Anderson Cancer Center, USC Keck School of Medicine, Massachusetts General Brigham, and the National University of Singapore. Eutropics is seeking venture-philanthropy investors who see the opportunity to underpin functional precision oncology across multiple drug portfolios with a scalable, revenue-generating diagnostic platform — delivering both patient impact and financial return. www.eutropics.com

Proteos is committed to providing a quality foundation for drug discovery. We are a contract research organization that provides the highest quality recombinant protein expression and purification services for drug discovery research in the biotechnology and pharmaceutical industries. Our highly-skilled team of scientists utilizes diverse experience and optimized methods within a customized workflow that focuses on the end product from square one. Fully customized experimental designs allow flexibility and adaptation during the project, thus enabling data-driven decisions that lead to a higher probability of project success. Proteos is passionate about drug discovery. We know that reliable reagents are critical for the ultimate success of drug discovery programs. Proteos is a wholly owned subsidiary of NIS, enabling a streamlined gene-to-structure workflow.